International Journal of PharmTech Research
CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563
Vol.13, No.03, pp 305-308, 2020

Hydroxychloroquine And Dexamethasone Are Both Possible For Treatment Of Covid-19

Hamza Khalifa[1]*, Ibrahim M Bendalla[1], Abdulfatah Saed[3], Samira Daw[4]

[1] Higher Institute of Medical Technology - Bani Waleed, Libya
[1]MCC Research Department - Bani Waleed, Libya
[2,3] Higher Institute of Medical Technology - Bani Waleed, Libya

Abstract : The antimalarial operators chloroquine and hydroxychloroquine have been utilized generally for the treatment of rheumatoid joint inflammation and fundamental lupus erythematosus. These mixes lead to progress of clinical and research facility parameters, however their moderate beginning of activity recognizes them from glucocorticoids and nonsteroidal mitigating operators. Chloroquine and hydroxychloroquine increment pH inside intracellular vacuoles and adjust procedures, for example, protein corruption by acidic hydrolases in the lysosome, get together of macromolecules in the endosomes, and posttranslation change of proteins in the Golgi mechanical assembly. It is suggested that the antirheumatic properties of these mixes results from their obstruction with "antigen preparing" in macrophages and other antigen-introducing cells. Acidic cytoplasmic compartments are required for the antigenic protein to be processed and for the peptides to collect with the alpha and beta chains of MHC class II proteins. Thus, antimalarials reduce the arrangement of peptide-MHC protein edifices required to animate CD4+ T cells and result in down-guideline of the safe reaction against autoantigenic peptides. Since this system varies from other antirheumatic drugs, antimalarials are appropriate to supplement these different mixes in blend medicate treatment[1].

Keywords : Covid-19, Coronavirus, Hydroxychloroquine, Dexamethasone, Treatment.

Hamza Khaliha *et al* /International Journal of PharmTech Research, 2020,13(3): 305-308.

DOI= http://dx.doi.org/10.20902/IJPTR.2019.130323

***** *****